Digging Deeper

 

https://www.cureus.com/articles/507304-botulinum-toxin-type-a-for-cervicogenic-headache-a-review-of-the-current-evidence#!/

New research highlights the ongoing discussion around Botulinum Toxin Type A (BoNT-A) as a treatment option for cervicogenic headache (CGH), a secondary headache disorder originating from structures in the neck and often associated with significant pain, disability, and reduced quality of life.

A recent review examined five clinical studies, including four randomised controlled trials, and found that most reported improvements in headache intensity and frequency following BoNT-A treatment, particularly in patients with chronic or treatment-resistant symptoms. The trapezius and splenius capitis muscles were the most commonly targeted injection sites.

However, the evidence remains mixed. One high-quality placebo-controlled trial found no significant benefit over placebo, and considerable variation existed across studies regarding diagnostic criteria, injection protocols, and outcome measures.

Key takeaway: BoNT-A appears to be a safe and potentially valuable option for some patients with cervicogenic headache, but stronger, standardised research is still needed before its role can be fully established.

At Act for Pain, we continue to follow the latest evidence to help ensure patients receive the most appropriate, evidence-based care for persistent headache and neck pain conditions. 

#ActForPain #PainManagement #CervicogenicHeadache #Botox #ChronicPain #HeadacheMedicine #EvidenceBasedPractice